NO986202D0 - FremgangsmÕte for fremstilling av rekombinant adÚnovirus - Google Patents

FremgangsmÕte for fremstilling av rekombinant adÚnovirus

Info

Publication number
NO986202D0
NO986202D0 NO986202A NO986202A NO986202D0 NO 986202 D0 NO986202 D0 NO 986202D0 NO 986202 A NO986202 A NO 986202A NO 986202 A NO986202 A NO 986202A NO 986202 D0 NO986202 D0 NO 986202D0
Authority
NO
Norway
Prior art keywords
adunovirus
recombinant
preparation
recombinant adunovirus
Prior art date
Application number
NO986202A
Other languages
English (en)
Other versions
NO986202L (no
Inventor
Fran Is Blanche
Jean-Marc Guillaume
Original Assignee
Rh Ne Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9608164A external-priority patent/FR2750433B1/fr
Application filed by Rh Ne Poulenc Rorer Sa filed Critical Rh Ne Poulenc Rorer Sa
Publication of NO986202D0 publication Critical patent/NO986202D0/no
Publication of NO986202L publication Critical patent/NO986202L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/20—Anion exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO986202A 1996-07-01 1998-12-30 FremgangsmÕte for fremstilling av rekombinant adÚnovirus NO986202L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9608164A FR2750433B1 (fr) 1996-07-01 1996-07-01 Procede de production d'adenovirus recombinants
US2666796P 1996-09-25 1996-09-25
PCT/FR1997/001107 WO1998000524A1 (fr) 1996-07-01 1997-06-20 Procede de production d'adenovirus recombinants

Publications (2)

Publication Number Publication Date
NO986202D0 true NO986202D0 (no) 1998-12-30
NO986202L NO986202L (no) 1999-02-15

Family

ID=26232805

Family Applications (1)

Application Number Title Priority Date Filing Date
NO986202A NO986202L (no) 1996-07-01 1998-12-30 FremgangsmÕte for fremstilling av rekombinant adÚnovirus

Country Status (13)

Country Link
US (3) US6485958B2 (no)
EP (1) EP0944717A1 (no)
JP (1) JP2000514290A (no)
KR (1) KR20050043996A (no)
AU (1) AU3447097A (no)
BR (1) BR9710030A (no)
CA (1) CA2258158A1 (no)
CZ (1) CZ438398A3 (no)
HU (1) HU224558B1 (no)
IL (1) IL127692A0 (no)
NO (1) NO986202L (no)
SK (1) SK181098A3 (no)
WO (1) WO1998000524A1 (no)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
AU3447097A (en) * 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
ATE550429T1 (de) * 1996-11-20 2012-04-15 Crucell Holland Bv Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
IL130198A (en) 1996-12-13 2005-09-25 Schering Corp Methods for purifying viruses
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6146891A (en) * 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EE200000605A (et) * 1998-04-22 2002-04-15 Genvec, Inc. Adenoviiruse efektiivne puhastamine
WO1999061643A1 (en) * 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
AU770672B2 (en) * 1998-05-27 2004-02-26 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CA2356373A1 (fr) * 1998-12-31 2000-07-13 Aventis Pharma S.A. Methode de separation de particules virales
FR2788064B1 (fr) * 1998-12-31 2003-01-31 Aventis Pharma Sa Methode de separation de particules virales
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US7319002B2 (en) * 2001-08-08 2008-01-15 The Trustees Of The University Of Pennsylvania Method for purification of viral vectors having proteins which bind sialic acid
JP4790984B2 (ja) * 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド アルファウイルスレプリコンベクター系
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
IL162404A0 (en) * 2002-01-18 2005-11-20 Schering Ag Stabilized formulations of adenovirus
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
EP1585964A4 (en) * 2002-08-28 2008-07-16 Introgen Therapeutics Inc CHROMATOGRAPHIC METHODS FOR PURIFYING ADENOVIRUSES
WO2004055167A2 (en) * 2002-12-13 2004-07-01 Alphavax, Inc. Alphavirus particles and methods for preparation
ES2618309T3 (es) * 2002-12-13 2017-06-21 Alphavax, Inc. Partículas de replicón de alfavirus multi-antigénico y métodos
ES2453344T3 (es) * 2003-03-20 2014-04-07 Alphavax, Inc. Replicones de alfavirus mejorados y constructos cooperadores
US20040229335A1 (en) 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
EP1633321A4 (en) * 2003-06-18 2006-11-02 Onyx Pharma Inc METHOD FOR CLEANING VIRUS
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
EP1718738A2 (en) * 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods
US20050266550A1 (en) 2004-05-18 2005-12-01 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
AU2005305347A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
WO2006057876A2 (en) * 2004-11-22 2006-06-01 Cedars-Sinai Medical Center Methods and solutions for tissue preservation
BRPI0609695A2 (pt) 2005-03-21 2011-10-18 Applera Corp composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença e uma paciente sofrendo uma terapia
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
US8465732B2 (en) 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
PE20081723A1 (es) 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
US8460913B2 (en) * 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
CA2742474C (en) * 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
NZ598000A (en) 2009-08-07 2013-10-25 Transgene Sa Composition for treating hbv infection
MX2012004222A (es) 2009-10-15 2012-06-08 Crucell Holland Bv Metodo para purificacion de particulas de adenovirus.
AU2010305768B2 (en) 2009-10-15 2015-05-14 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
CA2819552C (en) 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
AU2013231423B2 (en) 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
KR20150021088A (ko) 2012-06-05 2015-02-27 디 오스트레일리언 내셔널 유니버시티 인터루킨-4 길항제를 이용한 백신접종
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
SG11201506624SA (en) * 2013-02-28 2015-09-29 Psioxus Therapuetics Ltd A process for the production of adenovirus
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
WO2014202570A1 (en) 2013-06-17 2014-12-24 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
GB201415579D0 (en) * 2014-09-03 2014-10-15 Psioxus Therapeutics Ltd A process
KR102393885B1 (ko) * 2014-06-27 2022-05-02 앤지오크린 바이오사이언스 인코포레이티드 아데노바이러스 e4orf1을 발현하는 신경 세포 및 그 제조 방법과 용도
JP2017529070A (ja) * 2014-08-27 2017-10-05 サイオクサス セラピューティクス リミテッド アデノウイルスの製造方法
EP3245218A4 (en) 2015-01-13 2018-10-03 Alfa Wassermann, Inc. Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN107466324B (zh) 2015-04-14 2022-01-14 扬森疫苗与预防公司 具有双向启动子的表达两种转基因的重组腺病毒
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
WO2017147265A1 (en) * 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3013639A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR102506895B1 (ko) 2016-04-05 2023-03-08 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US11473105B2 (en) 2016-05-12 2022-10-18 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018093932A2 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
US11203629B2 (en) 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
CN110913892A (zh) 2017-05-02 2020-03-24 免疫治疗有限公司 包含癌抗原的lamp(溶酶体相关膜蛋白)构建物
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
KR20200053518A (ko) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 면역의 안전한 유도를 위한 방법
WO2019222281A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
JOP20210186A1 (ar) 2019-01-10 2023-01-30 Janssen Biotech Inc مستضدات البروستاتا المستحدثة واستخداماتها
JP2022521268A (ja) 2019-02-21 2022-04-06 アンリーシュ イミュノ オンカリティクス，インコーポレイテッド 腫瘍溶解性アデノウイルスベクター及び使用法
AU2020366515A1 (en) 2019-10-18 2022-04-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
US12018289B2 (en) 2019-11-18 2024-06-25 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
US20210315986A1 (en) 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4176087A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
EP4175721A1 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
AU2023254186A1 (en) 2022-04-10 2024-10-17 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2181066A1 (en) * 1994-01-12 1995-07-20 Hitoshi Kotani Purification of retroviral vectors
FR2716893B1 (fr) 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
EP0751988B1 (en) * 1994-03-22 2000-02-09 The Immune Response Corporation Highly efficient production and isolation of viral particles
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
AU3447097A (en) * 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
ATE550429T1 (de) 1996-11-20 2012-04-15 Crucell Holland Bv Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2356373A1 (fr) * 1998-12-31 2000-07-13 Aventis Pharma S.A. Methode de separation de particules virales

Also Published As

Publication number Publication date
US20020028497A1 (en) 2002-03-07
US6485958B2 (en) 2002-11-26
HUP0001271A3 (en) 2002-01-28
HU224558B1 (hu) 2005-10-28
WO1998000524A1 (fr) 1998-01-08
IL127692A0 (en) 1999-10-28
BR9710030A (pt) 1999-08-10
EP0944717A1 (fr) 1999-09-29
SK181098A3 (en) 1999-07-12
US20030143730A1 (en) 2003-07-31
US20050287657A1 (en) 2005-12-29
AU3447097A (en) 1998-01-21
CZ438398A3 (cs) 1999-03-17
HUP0001271A1 (hu) 2000-08-28
US6905862B2 (en) 2005-06-14
CA2258158A1 (fr) 1998-01-08
JP2000514290A (ja) 2000-10-31
NO986202L (no) 1999-02-15
KR20050043996A (ko) 2005-05-11

Similar Documents

Publication Publication Date Title
NO986202L (no) FremgangsmÕte for fremstilling av rekombinant adÚnovirus
NO307961B1 (no) FremgangsmÕte for fremstilling av en ester
NO990059L (no) Analoger av kationiske proteiner
NO993068L (no) Ny forbindelsesform
HUP9904239A3 (en) High level expression of proteins
NO994757L (no) Fremgangsmåte for oral administrasjon av proteiner
FI965268A (fi) Menetelmä moniarvoisten alkoholien valmistamiseksi
NO986177L (no) FremgangsmÕte for fremstilling av terapeutisk DNA
EE04154B1 (et) Omeprasooli valmistamise meetod
NO983913D0 (no) Fremgangsmåte for oppfanging av tioler
ID16451A (id) Metode pembuatan filamen-filamen liosel
DK0874822T3 (da) Ny fremgangsmåde til fremstilling
ID16838A (id) Komposisi dekafluoropentana
ID18300A (id) Metoda penemperan
HUP9903744A3 (en) Method of omeprazole preparation
ID20291A (id) Asam-asam oksobutirat tersubstitusi sebagai penghamba-penghambat matriks metaloproteasa
ID19540A (id) Metode pembuatan turunan-turunan benzofenon
NO992531D0 (no) FremgangsmÕter ved fremstilling av rekombinant protein
ID17419A (id) Komposisi dekafluoropentana
NO991148L (no) Fremstilling av 1-butyl-4-piperidinyl-metylamin
ID23019A (id) Metode pembuatan turunan nitroguadinin
ID19111A (id) Metoda pembuatan bahan-bahan poliolefin untuk pelapisan
EE9900404A (et) Arüülaminotriasolopüridiinide valmistamise meetod
UA25135A (uk) Спосіб гастроєюhопластики
UA25353A (uk) Спосіб холецистостомії

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application